BIO-TECHNE CORP's ticker is TECH and the CUSIP is 09073M104. A total of 289 filers reported holding BIO-TECHNE CORP in Q3 2017. The put-call ratio across all filers is 1.04 and the average weighting 0.2%.
About BIO-TECHNE CORP
Bio-Techne Corp is a leading provider of innovative life science research tools and diagnostic solutions. The company is headquartered in Minneapolis, Minnesota, and has operations in over 50 countries worldwide. Bio-Techne's products and services are used by researchers and clinicians in a wide range of fields, including cancer research, stem cell research, and immunology.
Bio-Techne's success is due in large part to its commitment to innovation and customer service. The company invests heavily in research and development, and has a team of over 1,000 scientists working to develop new products and technologies. Bio-Techne also has a strong focus on customer service, with a dedicated team of technical support specialists available to assist customers with any questions or issues they may have.
In addition to its research tools and diagnostic solutions, Bio-Techne also has a growing portfolio of clinical diagnostic products. The company's Exosome Diagnostics subsidiary is a leader in the development of liquid biopsy tests for cancer diagnosis and monitoring.
Bio-Techne's leadership team is comprised of experienced executives with a track record of success in the life sciences industry. Charles Kummeth, the company's CEO, has been with Bio-Techne since 2013 and has overseen significant growth and expansion during his tenure.
Overall, Bio-Techne is a company with a strong reputation for innovation, customer service, and leadership in the life sciences industry. With a growing portfolio of products and services, the company is well-positioned for continued success in the years to come.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2018 | $2,046,000 | -27.3% | 10,025 | -47.3% | 0.73% | -32.2% |
| Q2 2018 | $2,816,000 | -64.9% | 19,033 | -64.1% | 1.08% | -44.0% |
| Q1 2018 | $8,018,000 | +16.0% | 53,083 | -0.5% | 1.93% | +16.7% |
| Q4 2017 | $6,913,000 | +0.2% | 53,363 | -6.5% | 1.65% | +1.4% |
| Q3 2017 | $6,902,000 | -4.0% | 57,094 | -6.7% | 1.63% | -8.0% |
| Q2 2017 | $7,192,000 | +18.3% | 61,208 | +2.4% | 1.77% | +17.2% |
| Q1 2017 | $6,078,000 | +30.9% | 59,798 | +32.4% | 1.51% | +21.0% |
| Q4 2016 | $4,645,000 | -6.3% | 45,174 | -0.2% | 1.25% | -9.7% |
| Q3 2016 | $4,955,000 | -73.9% | 45,254 | -73.1% | 1.38% | -48.3% |
| Q2 2016 | $18,952,000 | +14.3% | 168,062 | -4.2% | 2.68% | +19.0% |
| Q1 2016 | $16,586,000 | +28.4% | 175,486 | +22.2% | 2.25% | +33.6% |
| Q4 2015 | $12,921,000 | +38.1% | 143,566 | +41.9% | 1.68% | +12.4% |
| Q3 2015 | $9,355,000 | – | 101,177 | – | 1.50% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Blue Water Life Science Advisors, LP | 46,500 | $16,119,000 | 8.75% |
| Montanaro Asset Management Ltd | 93,950 | $32,567,000 | 4.90% |
| Jackson Square Partners, LLC | 556,157 | $192,786,000 | 4.50% |
| STONE RUN CAPITAL, LLC | 22,405 | $7,767,000 | 3.91% |
| Ownership Capital B.V. | 655,654 | $227,276,000 | 3.90% |
| Brown Capital Management | 839,587 | $291,034,000 | 3.90% |
| Sandhill Capital Partners LLC | 97,382 | $33,757,000 | 3.61% |
| DF DENT & CO INC | 684,026 | $237,111,000 | 3.34% |
| Westwind Capital | 27,946 | $9,687,000 | 3.17% |
| MAIRS & POWER INC | 655,930 | $227,371,000 | 2.72% |